Previous Article | Next Article ![]()
Journal of Virology, December 2000, p. 11972-11976, Vol. 74, No. 24
Department of Cancer Immunology and AIDS,
Dana-Farber Cancer Institute, Harvard Medical
School,1 Department of Immunology and
Infectious Diseases, Harvard School of Public
Health,2 and Perlmutter Laboratory,
Children's Hospital, and Department of Medicine and Pediatrics, Beth
Israel Hospital and Harvard Medical School,4
Boston, Massachusetts 02115; Pharmaceutical Discovery Research
Division, Takeda Chemical Industries, Ltd., Tsukuba, Ibaraki
300-4293, Japan3; Ethiopian Health and
Nutrition Research Institute, Addis Ababa,
Ethiopia5; and Department of Human
Retrovirology, Faculty of Medicine-Academic Medical Centre,
University of Amsterdam, Amsterdam, The
Netherlands6
Received 6 April 2000/Accepted 22 August 2000
In addition to the CCR5 and CXCR4 chemokine receptors, a subset of
primary human immunodeficiency virus type 1 (HIV-1) isolates can also
use the seven-transmembrane-domain receptor APJ as a coreceptor. A
previously identified ligand of APJ, apelin, specifically inhibited the
entry of primary T-tropic and dualtropic HIV-1 isolates from different
clades into cells expressing CD4 and APJ. Analysis of apelin analogues
demonstrated that potent and specific antiviral activity was retained
by a 13-residue, arginine-rich peptide. Antiviral potency was
influenced by the integrity of methionine 75, which contributes to
APJ-binding affinity, and by the retention of apelin residues 63 to 65. These studies demonstrate the ability of a small peptide ligand to
block the function of APJ as an HIV-1 coreceptor, identify apelin
sequences important for the inhibition, and provide new reagents for
the investigation of the significance of APJ to HIV-1 infection and pathogenesis.
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Apelin, the Natural Ligand of the Orphan Seven-Transmembrane
Receptor APJ, Inhibits Human Immunodeficiency Virus Type 1 Entry
*
Corresponding author. Mailing address: Dana-Farber
Cancer Institute, 44 Binney St.-JFB 824, Boston, MA 02115. Phone: (617) 632-3371. Fax: (617) 632-4338. E-mail:
joseph_sodroski{at}dfci.harvard.edu.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»